UB Paderborn / Katalog / Suche / in CDI

Endogenous probes for transporter-mediated drug–drug interaction

Drug metabolism and pharmacokinetics, 2018-01, Vol.33 (1), p.S7-S7

Lai, Yurong

2018

Link zum Volltext

Verfügbarkeit prüfen

Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion

Expert opinion on drug metabolism & toxicology, 2009-10, Vol.5 (10), p.1175-1187

Lai, Yurong

2009

Link zum Volltext

Verfügbarkeit prüfen

Organic Anion Transporter 2: An Enigmatic Human Solute Carrier

Drug metabolism and disposition, 2017-02, Vol.45 (2), p.228-236

2017

Link zum Volltext

Verfügbarkeit prüfen

Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug Interactions

Journal of medicinal chemistry, 2012-05, Vol.55 (10), p.4740-4763

2012

Link zum Volltext

Verfügbarkeit prüfen

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

Clinical pharmacology and therapeutics, 2018-11, Vol.104 (5), p.836-864

2018

Link zum Volltext

Verfügbarkeit prüfen

Protein Abundance of Clinically Relevant Multidrug Transporters along the Entire Length of the Human Intestine

Molecular pharmaceutics, 2014-10, Vol.11 (10), p.3547-3555

2014

Link zum Volltext

Verfügbarkeit prüfen

Editorial: Clinical trials in drug metabolism and transport: 2022

Frontiers in pharmacology, 2023-06, Vol.14, p.1223428-1223428

2023

Link zum Volltext

Verfügbarkeit prüfen

The Role of Coproporphyrins As Endogenous Biomarkers for Organic Anion Transporting Polypeptide 1B Inhibition-Progress from 2016 to 2023

Drug metabolism and disposition, 2023-08, Vol.51 (8), p.950

Lai, Yurong

2023

Link zum Volltext

Verfügbarkeit prüfen

Toward a Consensus on Applying Quantitative Liquid Chromatography‐Tandem Mass Spectrometry Proteomics in Translational Pharmacology Research: A White Paper

Clinical pharmacology and therapeutics, 2019-09, Vol.106 (3), p.525-543

2019

Link zum Volltext

Verfügbarkeit prüfen

Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions

Drug metabolism and disposition, 2014-07, Vol.42 (7), p.1210

2014

Link zum Volltext

Verfügbarkeit prüfen

Interindividual Variability in the Hepatic Expression of the Human Breast Cancer Resistance Protein (BCRP/ABCG2): Effect of Age, Sex, and Genotype

Journal of pharmaceutical sciences, 2013-03, Vol.102 (3), p.787-793

2013

Link zum Volltext

Verfügbarkeit prüfen

Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities

Drug metabolism and disposition, 2019-10, Vol.47 (10), p.1122-1135

2019

Link zum Volltext

Verfügbarkeit prüfen

Interindividual and Regional Variability in Drug Transporter Abundance at the Human Blood–Brain Barrier Measured by Quantitative Targeted Proteomics

Clinical pharmacology and therapeutics, 2019-07, Vol.106 (1), p.228-237

2019

Link zum Volltext

Verfügbarkeit prüfen

Transporter Gene Regulation in Sandwich Cultured Human Hepatocytes Through the Activation of Constitutive Androstane Receptor (CAR) or Aryl Hydrocarbon Receptor (AhR)

Frontiers in pharmacology, 2021-01, Vol.11, p.620197-620197

2021

Link zum Volltext

Verfügbarkeit prüfen

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data

Drug metabolism and disposition, 2012-05, Vol.40 (5), p.1007

2012

Link zum Volltext

Verfügbarkeit prüfen

Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?

Drug metabolism and disposition, 2020-03, Vol.48 (3), p.205-216

2020

Link zum Volltext

Verfügbarkeit prüfen

Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic considerations beyond the direct inhibition of the bile salt export pump

Drug metabolism and disposition, 2014-04, Vol.42 (4), p.566

2014

Link zum Volltext

Verfügbarkeit prüfen

Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study

Drug metabolism and disposition, 2018-07, Vol.46 (7), p.943-952

2018

Link zum Volltext

Verfügbarkeit prüfen

Positron Emission Tomography Imaging of [11C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A

Clinical pharmacology and therapeutics, 2019-11, Vol.106 (5), p.1056-1066

2019

Link zum Volltext

Verfügbarkeit prüfen

Intestinal P‐gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications

Clinical pharmacology and therapeutics, 2021-01, Vol.109 (1), p.55-64

2021

Link zum Volltext

Verfügbarkeit prüfen

Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective

Clinical pharmacology and therapeutics, 2018-11, Vol.104 (5), p.916-932

2018

Link zum Volltext

Verfügbarkeit prüfen

Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition

Drug metabolism and disposition, 2018-08, Vol.46 (8), p.1075-1082

2018

Link zum Volltext

Verfügbarkeit prüfen

Coproporphyrin-I: A Fluorescent, Endogenous Optimal Probe Substrate for ABCC2 (MRP2) Suitable for Vesicle-Based MRP2 Inhibition Assay

Drug metabolism and disposition, 2017-06, Vol.45 (6), p.604-611

2017

Link zum Volltext

Verfügbarkeit prüfen

Development of a new permeability assay using low‐efflux MDCKII cells

Journal of pharmaceutical sciences, 2011-11, Vol.100 (11), p.4974-4985

2011

Link zum Volltext

Verfügbarkeit prüfen

Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition

Drug metabolism and disposition, 2020-08, Vol.48 (8), p.724-734

2020

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Endogenous probes for transporter-mediated drug–drug interaction

Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion

Organic Anion Transporter 2: An Enigmatic Human Solute Carrier

Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug Interactions

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

Protein Abundance of Clinically Relevant Multidrug Transporters along the Entire Length of the Human Intestine

Editorial: Clinical trials in drug metabolism and transport: 2022

The Role of Coproporphyrins As Endogenous Biomarkers for Organic Anion Transporting Polypeptide 1B Inhibition-Progress from 2016 to 2023

Toward a Consensus on Applying Quantitative Liquid Chromatography‐Tandem Mass Spectrometry Proteomics in Translational Pharmacology Research: A White Paper

Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions

Interindividual Variability in the Hepatic Expression of the Human Breast Cancer Resistance Protein (BCRP/ABCG2): Effect of Age, Sex, and Genotype

Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities

Interindividual and Regional Variability in Drug Transporter Abundance at the Human Blood–Brain Barrier Measured by Quantitative Targeted Proteomics

Transporter Gene Regulation in Sandwich Cultured Human Hepatocytes Through the Activation of Constitutive Androstane Receptor (CAR) or Aryl Hydrocarbon Receptor (AhR)

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data

Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?

Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic considerations beyond the direct inhibition of the bile salt export pump

Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study

Positron Emission Tomography Imaging of [11C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A

Intestinal P‐gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications

Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective

Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition

Coproporphyrin-I: A Fluorescent, Endogenous Optimal Probe Substrate for ABCC2 (MRP2) Suitable for Vesicle-Based MRP2 Inhibition Assay

Development of a new permeability assay using low‐efflux MDCKII cells

Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition

Suchergebnisse filtern